Read Editorial with D2G – Ep 516

Read Editorial with D2G – Ep 516

Return to frontpage

Scientific disinterest: On Health Minister’s presence at Coronil promotion event

D2G wears no responsibility of the views published here by the respective Author. This Editorial is used here for Study Purpose. Students are advised to learn the word-meaning, The Art of Writing Skills and understand the crux of this Editorial.

Read Editorial

 Meanings are given in BOLD

The presence of Union Health Minister Harsh Vardhan at a press conference to promote Coronil, an Ayurvedic pill promoted by Baba Ramdev’s Patanjali Ayurved, is objectionable ( very unpleasant ) on more than one count. Coronil is a concoction ( an elaborate story, especially a fabricated one ) of common herbs known to Ayurveda. Since June, there have been attempts to deploy ( bring into effective action ) it into India’s COVID-19 management protocol.

Dr Vardhan, alongside Cabinet colleague Nitin Gadkari, was at a press conference with Baba Ramdev and other promoters of Patanjali to announce a scientific publication describing the efficacy ( the ability to produce a desired or intended result ) of Coronil in ridding ( make someone or something free of (an unwanted person or thing) ) volunteers, part of a clinical trial, of coronavirus.

For one, Coronil is a product manufactured by a private company. Doctors — Harsh Vardhan is an ENT surgeon — are explicitly ( in a clear and detailed manner, leaving no room for confusion or doubt ) barred ( forbid someone from undertaking (an activity) ) from promoting drugs of any sort. Though Dr Vardhan didn’t explicitly mention Coronil in his address at the function, what public functionaries are seen to be doing speaks louder than what they say.

Baba Ramdev first claimed that his product was endorsed ( declare one’s public approval or support of ) by the WHO. Following media reports, WHO South-East Asia tweeted that it hadn’t reviewed or certified the effectiveness of any traditional medicine for the treatment of COVID-19.

What transpired ( (of a secret or something unknown) come to be known; be revealed ) was that India’s apex ( the top or highest part of something, especially one forming a point ) drug regulator had certified Coronil as a pharmaceutical product in “supporting COVID treatment and an immunity booster” and cleared it for export. It hasn’t recommended it as treatment for COVID-19.

The publication of a double-blinded, randomised clinical trial in a research journal isn’t an endorsement ( approval ; acceptance ) of a product, but an essential requirement of reporting the drug’s action to subject experts. The report reveals that the medicine was only tested on 95 of those asymptomatic and “mildly symptomatic” but confirmed as RT-PCR positive.

The 45 patients who got the actual treatment (and not a dummy pill) tested COVID-19 negative significantly quicker. However, these numbers are small. A large proportion of those with mild or no symptoms are expected to clear out the infection without any external intervention ( action taken to improve a medical disorder ). There was no information in the study on the number of days that elapsed ( pass or go by ) before the patients tested positive, making the role of the drug in clearing out the virus unclear.

True, allopathic medicine too has cut corners: an ICMR-led trial ultimately couldn’t justify the administration of hydroxychloroquine; the Drugs Controller General of India approved itolizumab by Biocon that was tested only in a sample of 30 but was advertised as a “breakthrough drug”; and Covaxin was approved before its efficacy ( the ability to produce a desired or intended result ) was known. Processes are imperfect, but the government must demonstrate its scientific disinterest when evidence ( proof ; verification ) is wanting ( lacking in a required or necessary quality ).

Check out our latest videos on youtube